Evaluating the contribution of genetic and familial shared environment to common disease using the UK Biobank by Munoz, Maria et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Evaluating the contribution of genetic and familial shared
environment to common disease using the UK Biobank
Citation for published version:
Munoz, M, Pong-Wong, R, Canela-Xandri, O, Rawlik, K, Haley, C & Tenesa, A 2016, 'Evaluating the
contribution of genetic and familial shared environment to common disease using the UK Biobank' Nature
Genetics, vol. 48, no. 9, pp. 980-983. DOI: 10.1038/ng.3618
Digital Object Identifier (DOI):
10.1038/ng.3618
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Peer reviewed version
Published In:
Nature Genetics
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 05. Apr. 2019
  
Title:  
Evaluating the contribution of genetic and familial shared environment to 
common disease using the UK Biobank 
Authors:   
María Muñoz1, Ricardo Pong-Wong1, Oriol Canela-Xandri1, Konrad Rawlik1, 
Chris S. Haley1,2, Albert Tenesa1,2,3  
  
Affiliations:  
1The Roslin Institute, Royal (Dick) School of Veterinary Studies, The University 
of Edinburgh, Easter Bush Campus, Midlothian, EH25 9RG, UK.  
2 MRC Human Genetics Unit at the MRC Institute of Genetics and Molecular 
Medicine, University of Edinburgh, Western General Hospital, Crewe Road 
South, Edinburgh, EH4 2XU, UK  
  
  
3 Corresponding author  
Dr Albert Tenesa  
The Roslin Institute  
The University of Edinburgh  
Easter Bush  
Roslin, Midlothian  
EH25 9RG  
UK 
Tel: 0044 (0)131 651 9100  
Fax: 0044 (0)131 651 9220  
Email: Albert.Tenesa@ed.ac.uk  
  
 
ABSTRACT 
Genome-wide association studies have detected many loci underlying 
susceptibility to disease, but most of the genetic factors that contribute 
  
to disease susceptibility remain unknown. Here we provide evidence that 
part of the missing heritability can be explained by an overestimation of 
heritability. We estimated the heritability of twelve complex human 
diseases using family history of disease in 1,555,906 white European 
individuals from the UK Biobank. Estimates using simple family-based 
statistical models were inflated on average by ~47% comparing with 
those from Structural Equation Models (SEM) that specifically accounted 
for shared familial environmental factors. In addition, heritabilities using 
SNP data explained an average of 44.2% of the simple family-based 
estimates across diseases and an average of 57.3% of SEM estimated 
heritability and accounted for almost all of the SEM heritability for 
hypertension. Our results show that both genetics and familial 
environment make substantial contributions to familial clustering of 
disease.  
  
INTRODUCTION 
The causation of most common human diseases is complex, being influenced 
by a combination of genetic and environmental factors1. The development of 
genome-wide association studies (GWAS) has allowed the detection of many 
genetic variants associated with these diseases. However, these variants only 
explain a fraction of the heritability estimated in previous family-based studies 
and hence there is a “missing heritability” that remains unidentified2. One 
possible explanation for this missing heritability is that previous heritability 
estimates could be inflated because family environmental effects were not 
specified in the model or because they could not be estimated due to the study 
design3. Furthermore, comparisons of heritability explained by SNPs identified 
through GWAS or the hidden heritability estimated from genome-wide arrays 
(that is, the SNP heritability which captures the contribution of common variants 
including those not yet detected as genome-wide significant due to lack of 
power) with published estimates of heritability possess some important 
challenges. For instance, the populations from which family-based heritability 
  
estimates were obtained may differ from those used in the GWAS studies in 
definition or prevalence of disease or genetic background. These, and other 
factors3, make assessments of heritability estimates for disease from familial 
and GWAS studies difficult and in some instances inappropriate. 
The objective of the current study was to estimate the heritability of twelve 
complex human diseases using self-reported personal and family history of 
disease in 1,555,906 white European participants and relatives from the UK 
Biobank, which comprise over 2% of the UK population. 
RESULTS 
Data overview and Relative Risks 
The UK Biobank contains disease and trait data, as well as biological samples 
collected from around 500,000 participants and has as its main objective to 
identify ways of improving the prevention, diagnosis and treatment of complex 
diseases4. UK Biobank participants were measured for multiple traits and 
questioned about their lifestyle, environmental risk factors and medical history 
and gave their informed consent following strict protocols5. Here we use 
information from the family disease history reported by participants to estimate 
the heritability and the environmental contributions to the liability of twelve 
broadly defined complex diseases: heart disease, stroke, chronic bronchitis, 
hypertension, diabetes, Alzheimer's disease, Parkinson's disease, severe 
depression and lung, bowel, prostate and breast cancers (Supplementary Table 
1). Accuracy of self-reported health status was assessed and is discussed in 
the supplementary information (Supplementary note and Supplementary Tables 
2 and 3).  
Disease prevalence was higher among men than among women for all 
diseases except for severe depression, which was more prevalent among 
women (Supplementary Table 4). Generally, disease prevalence was higher 
among the parents of the participants than among the participants and their 
siblings, suggesting an age-related increase in disease liability. The relative 
risks (RR) of parents (RRPO) and siblings (RRSIB) of ill individuals participating in 
  
UK Biobank were estimated for each disease. In addition, the relative risk for 
partners of affected individuals was estimated using information from the 
parents of the participants (RRPAR). All the relative risks were significantly larger 
than one (Supplementary Figure 1). Overall, the relative risks for the estimates 
of RRPO and RRSIB that combined information from blood and adopted relatives 
were higher than those for RRPAR, except for hypertension and lung cancer. 
These estimates of relative risks suggest that combinations of both genetics 
and shared environmental risk factors contribute to the causation of these 
diseases (Supplementary Figure 1).  
Heritability Estimates using Falconer’s Method 
We estimated heritability values (h2) from either the correlations or regression 
coefficients (b) of the first-degree family pairs: parents-offspring (participants), 
siblings-participants and parents-siblings of participants (to provide h2PO, h2SIB, 
and h2PSIB, respectively) following Falconer’s Method (Methods). Correlations or 
regression coefficients using information of adoptive parent-offspring (bAPO) and 
adoptive sibling (bASIB) pairs, and parents of participants (partners, bPAR) were 
also calculated. Estimates among concordant and discordant gender pairs were 
calculated using a method that takes into account differences between sexes1, 
then these estimates were combined using a weighted mean of b across all 
gender pairs. Across generation differences in disease prevalence were taken 
into account using a control population of the same age for comparison1. 
Genetic correlations between genders were close to one, but tended to be lower 
than one (Supplementary Table 5). 
All heritability estimates from first-degree family pairs were significantly different 
from zero (Table 1). The highest h2PO value was noted for depression 
(0.491±0.007) whereas the highest h2SIB was observed for prostate cancer 
(0.707±0.062). Estimates of h2PO were significantly lower than those of h2SIB for 
heart disease, stroke, hypertension, diabetes, and prostate and breast cancers, 
suggesting the existence of non-additive genetic effects or a greater 
environmental similarity between siblings than between parents and their 
children. The highest value of the regression from adoptive parent-offspring 
  
pairs, bAPO, was observed for severe depression (0.250±0.036) suggesting an 
important influence of shared family environmental effects on this disease. The 
adoptive parent-offspring regression, although much smaller than for 
depression, was also significantly greater than zero for heart disease, bronchitis 
and breast cancer. Hypertension had a high value for the correlation between 
partners, bPAR, (0.203±0.002) and a low value for bAPO (0.035±0.021) indicating 
the importance of environmental effects shared by partners but that are not 
shared between parents and their offspring, and/or positive assortative mating 
for hypertension or a trait or combination of traits highly correlated with 
hypertension.  
Significant positive regression or correlation coefficients from adopted pairs and 
partners (e.g. parents of participants) suggest the potential existence of various 
environmental effects shared by family members. Hence estimates of heritability 
obtained using only blood relatives or from models that do not account for the 
full complexity of shared environmental effects may be inflated (Supplementary 
Table 6)6-13.  
Heritability Estimates using Structural Equation Modelling 
Heritabilities estimated from SEM were in general lower than those estimated 
using Falconer’s method, with significant family environmental effects detected 
for all the diseases except for Parkinson’s disease (Table 2, Supplementary 
Table 7). Although for most diseases, genetic effects were the major attributable 
contribution to disease liability, for hypertension the sum of the effects due to 
shared familial environment was more important than genetic effects (A = 0.28 
and C+S+P = 0.33). The estimated partner effect (P = 0.13) for hypertension 
and the common family effect (C = 0.15) for depression were high. High values 
of P inform about shared environment among partners or perhaps the presence 
of assortative mating. The physiological nature of hypertension mitigates 
against the possibility of assortative mating and it seems more likely that the 
high estimate for P is due to environmental factors shared by partners such as 
diet. However we cannot conclusively differentiate among these possibilities 
without more information such as the length of cohabitation14. The relatively 
large estimate of the common family effect for depression (C=0.15) would 
  
account for approximately half the correlation in the liability for depression 
between first degree relatives (as the expected correlation = A/2 + C) and would 
be important to consider in future studies of depression. Similarly our estimates 
suggest that at least a half of the correlation in disease liability between siblings 
is due to the combined effects of common family (C) and sibling (S) 
environment for heart disease, hypertension and lung cancer. 
Simulations 
To test the performance of our analytical methods we simulated data for the 
twelve different diseases using the genetic and environmental contributions to 
liability estimated under the full model for each disease and the corresponding 
values of prevalence for fathers, mothers, participants and siblings 
(Supplementary Table 8). We analyzed ten replicated simulations for each 
disease to estimate the liability components. The means of liability components 
of the ten replicates were similar to those used to perform the simulations 
(Supplementary Tables 8 and 9). Performing model comparison within each 
replicate (Methods), recovered the model used to simulate data in more than 
50% of the replicates for 4 of the 12 diseases (heart disease, hypertension, 
severe depression and prostate cancer) (Supplementary Table 10). However, 
even for the instances where the true generating model was not recovered, the 
means of genetic parameters across replicates were similar to those used to 
simulate data (Supplementary Table 11). Fitting an AE model ignoring familial 
environment to the simulated data yielded an overestimation of the heritability 
for all diseases (Supplementary Table 12). 
Heritability using SNPs 
We obtained SNP heritability estimates using 525,242 SNPs in the genotyped 
subsample of 114,264 unrelated individuals for those diseases with prevalence 
higher than 0.50% (Methods). The SNPs explained an average of 44.2% of the 
Falconer’s method estimates, 44.0% of the SEM family–based heritability 
estimates using the AE model (Omitting family environmental factors - 
Supplementary Table 13) and 57.3% of the SEM family–based heritability 
  
estimates under the most parsimonious adequate model including family 
environmental factors, respectively, across diseases. The SNP heritability 
explained ~100% of the SEM heritability estimate for hypertension (Figure 1, 
Table 3), which suggests that, for this high-prevalence disease where we could 
model a large number of familial environmental factors, there might be little or 
no missing heritability. Conclusions from SNP heritability estimates were similar 
when SNPs were split into common and rare minor allele frequency (MAF) 
groups and the joint heritabilities of these two groups were estimated 
(Supplementary Table 14). However, as previously reported by Mancuso et al15 
and Yang et al16 and) these estimates were generally slightly lower than 
estimates based on a single variance component of common and rare variants.  
SNP heritability estimates from self-reported and medical records 
(Supplementary Table 15) were not significantly different from each other, 
supporting the usefulness of the self-reported records. This was further 
confirmed by the similarity in the number of published GWAS hits with 
significant associations in the UK Biobank data using the self-reported definition 
of disease or the definition of disease from medical records (Supplementary 
Table 16). 
DISCUSION 
In the current study, we estimated the heritabilities of twelve diseases from 
family-based data using a model which does not take into account 
environmental factors shared by the family members (Falconer’s method) and a 
SEM method which enables joint estimation of these environmental factors and 
genetic factors. For most diseases, we obtained lower heritability values with 
the SEM method than with Falconer’s method associated with significant shared 
environmental effects. Therefore, the heritability estimates using SNPs were 
closer to SEM family-based heritability values than to those from Falconer’s 
method. Indeed for hypertension the heritability estimates using SNPs was 
similar to the SEM family-based heritability. 
  
Recently, Yang et al16 have used information from simulated and observed data 
and analysis of high density imputed data to conclude that there is limited 
evidence for missing heritability for height and BMI once potential 
overestimation of heritability in family-based studies is taken into account. 
Zaitlen et al17 studied twenty three traits in the Icelandic population and 
suggested that most of the “missing heritability” is likely due to rare variants not 
included in the genotyping array but also reported that the excess correlation 
among close relatives was mostly accounted for by shared environment. Finally, 
Liu et al18 have also shown that models accounting for a diverse source of 
shared environmental effects should be tested to avoid bias in heritability 
estimation for a number of quantitative traits. In agreement with Zaitlen et al17, 
our very large study provides evidence that part of the missing heritability may 
be due to previous inflated heritability estimates and demonstrates this for 
important binary disease traits. 
This study was based on a large cohort from the UK population, allowing us to 
estimate heritability with much narrower confidence intervals than in previous 
studies. In addition, models accounting for different environmental components 
shared by family members could be implemented due to the information 
available for different first-degree blood and adoptive relatives. The twelve 
diseases analyzed in this large cohort of individuals show significant but 
moderate values of heritability and an important impact of shared familial 
environmental effects and support the case for combining these factors with 
genetic marker information in order to improve the performance of disease-risk 
prediction methods19,20. Our results are very relevant when assessing the 
potential for the development of personalized medicine, providing realistic 
expectations of the value of genetic testing. In addition, demonstration of the 
importance of environmental risk factors that contribute to the aggregation of 
disease within families motivates research to identify and moderate these 
factors. 
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Figure 1. Heritability estimates using SEM family-based models (self-reported 
data) and SNPs (self-reported data and medical records). 
Black and grey sets show the three heritability estimates for each disease using 
SEM family-based models (self-reported data) and SNPs (self-reported data and 
medical records). 
 
  
Table 1. Family-based heritability estimates not accounting for shared environmental effects calculated by Falconer’s 
method and regression coefficients derived from different relative pairs.  
Disease  h2PO (SE) h2SIB (SE) h2PSIB (SE) bAPO (SE) bASIB (SE) bPAR (SE) 
Heart Disease 0.368 (0.005) 0.557 (0.018) 0.514 (0.010) 0.114 (0.026) 0.145 (0.108) 0.151 (0.003) 
Stroke 0.162 (0.010) 0.305 (0.044) 0.260 (0.017) -0.057 (0.054) - 0.038 (0.004) 
Bronchitis 0.420 (0.009) 0.501 (0.034) 0.567 (0.017) 0.169 (0.039) 0.338 (0.138) 0.108 (0.005) 
Hypertension 0.366 (0.009) 0.691 (0.010) 0.477 (0.008) 0.035 (0.021) 0.190 (0.056) 0.203 (0.002) 
Diabetes 0.474 (0.007) 0.692 (0.019) 0.485 (0.012) 0.067 (0.037) 0.185 (0.098) 0.109 (0.004) 
Alzheimer’s 0.238 (0.061) - 0.349 (0.036) - - 0.060 (0.005) 
Parkinson’s 0.247 (0.038) - 0.214 (0.053) - - 0.028 (0.013) 
Depression 0.491 (0.007) 0.443 (0.019) 0.642 (0.013) 0.250 (0.036) 0.184 (0.083) 0.162 (0.005) 
Lung cancer 0.117 (0.038) - 0.314 (0.025) - - 0.119 (0.005) 
Bowel cancer 0.260 (0.017) 0.387 (0.057) 0.300 (0.023) 0.171 (0.120) - 0.032 (0.005) 
Prostate cancer 0.361 (0.022)¥ 0.707 (0.062)¥ 0.321 (0.036) ¥ -0.053 (0.183) - - 
Breast cancer 0.287 (0.014)Ψ 0.393 (0.039)Ψ 0.301 (0.025)Ψ 0.144 (0.070) - - 
h2PO: heritability estimates using data of parents and offspring; (SE): Standard errors between brackets; h2SIB: heritability estimates 
using data of siblings; h2PSIB: heritability estimates using data of parents and siblings of participants; bAPO: regression coefficient of 
parents on adopted offspring; bASIB: regression coefficient of adoptive siblings; bPAR regression coefficient of parents of participants 
(partners); -: Effect was not estimated as there was less than one pair with both members affected;  ¥Only male-male pairs; ΨOnly 
female-female pairs.  
  
Table 2. Genetic and environmental effects estimated using the parsimonious reduced SEM model.  
Disease Model A (CI±0.95) C (CI±0.95) S (CI±0.95) P (CI±0.95) E (CI±0.95) 
Heart Disease ACSPE 0.27 (0.24-0.27) 0.08 (0.07-0.12) 0.08 (0.07-0.08) 0.06 (0.06-0.07) 0.51 (0.49-0.57) 
Stroke APE 0.23 (0.21-0.25) - - 0.04 (0.03-0.04) 0.73 (0.71-0.76) 
Bronchitis ACE 0.29 (0.25-0.33) 0.10 (0.10-0.11) - - 0.61 (0.60-0.64) 
Hypertension ACSPE 0.28 (0.28-0.29) 0.06 (0.06-0.06) 0.14 (0.14-0.14) 0.13 (0.12-0.13) 0.39 (0.38-0.39) 
Diabetes ASPE 0.50 (0.49-0.52) - 0.11 (0.09-0.13) 0.07 (0.06-0.08) 0.32 (0.29-0.34) 
Alzheimer’s ACE 0.25 (0.17-0.33) 0.05 (0.03-0.06) - - 0.70 (0.63-0.78) 
Parkinson’s AE 0.26 (0.20-0.34) - - - 0.74 (0.72-0.81) 
Depression ACE 0.25 (0.21-0.29) 0.15 (0.15-0.15) - - 0.60 (0.58-0.63) 
Lung cancer ACE 0.09 (0.02-0.14) 0.11 (0.09-0.13) - - 0.81 (0.75-0.86) 
Bowel cancer ACSE 0.24 (0.21-0.26) 0.03 (0.01-0.03) 0.06 (0.03-0.12) - 0.67 (0.65-0.71) 
Prostate cancer ASE 0.38 (0.32-0.44)  - 0.19 (0.11-0.26) - 0.43 (0.36-0.51) 
Breast cancer ASE 0.29 (0.26-0.33) - 0.06 (0.01-0.10) - 0.65 (0.60-0.69) 
A: Additive genetic effects; C: Environmental effects common to the whole family; S: Sibling environmental effects; P: Partner 
environmental effects; E: Residual environmental effect; Confidence Interval at 95% between brackets. -: Parameter dropped from 
parsimonious reduced model. 
  
Table 3. Heritability estimates of disease using common + rare SNPs 
and structural equation modelling (SEM) from self-reported data. 
Disease h2C+R (CI95%) h2SEM (CI95%) %(h2 C+R /h2SEM) (SE) 
Heart Disease 0.11 (0.08-0.15) 0.27 (0.24-0.27) 40.74 (9.79) 
Stroke 0.09 (0.00-0.17) 0.23 (0.21-0.25) 39.13 (29.07) 
Bronchitis 0.16 (0.10-0.22) 0.29 (0.25-0.33) 54.43 (15.72) 
Hypertension 0.32 (0.30-0.34) 0.28 (0.28-0.29) 114.29 (3.29) 
Diabetes 0.35 (0.30-0.39) 0.50 (0.49-0.52) 70.00 (5.23) 
Depression 0.07 (0.03-0.10) 0.25 (0.23-0.27) 24.00 (13.79) 
Bowel cancer 0.12 (0.00-0.28) 0.24 (0.21-0.26) 50.0 (49.75) 
Prostate cancer 0.23 (0.06-0.40) 0.38 (0.32-0.44)  60.53 (30.42) 
Breast cancer 0.18 (0.10-0.26) 0.29 (0.26-0.33) 62.07 (19.05) 
h2C+R: Heritability estimates using SNPs in the liability scale; (CI95%): 
Confidence intervals; %(h2C+R /h2SEM): Percentage of SEM family-based 
estimate of heritability explained by SNPs. (SE): Standard error 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
ONLINE METHODS  
UK Biobank Data 
The UK Biobank database) includes 502,682 participants who were aged 
between 49-69 years when recruited between 2006 and 2010 from across UK 
to take part of the project. The study was approved by the National Research 
Ethics Committee (REC reference: 11/NW/0382). The participants filled 
several questionnaires about their lifestyle, environmental risk factors and 
medical history and gave their informed consent4. The comprehension and 
acceptability of each question, the time taken to complete each of them, and 
their response distributions were examined in pilot studies, which aided the 
final selection and presentation of suitable questions. Self-reported medical 
history was confirmed by a trained nurse and where necessary by a medical 
doctor. Moreover, a pre-visit questionnaire was provided to participants before 
attending the assessment center, this questionnaire afforded participants the 
opportunity to record personal information such as family history before the 
visit to the assessment center to minimize problems of recalling. These details 
were entered directly into the assessment center computer and the 
questionnaire was not retained5. The UK Biobank contains information on 
about 445 types of diseases and 81 cancers in participants and the familial 
medical history of twelve broadly defined diseases among blood and adoptive 
fathers, mothers and siblings. Participants were considered as adopted when 
they answer “Yes” to the question: “Were you adopted as a child?”. 
Family pairs (parent-offspring, sib-sib, parent-sibs and partners) were 
characterized for these twelve diseases, which include different subcategories 
in participants. The diseases analyzed were: heart disease (twenty-five 
subcategories), stroke (three subcategories), chronic bronchitis (three 
subcategories), hypertension (two subcategories), diabetes (four 
subcategories), Alzheimer's disease, Parkinson's disease, severe depression, 
lung cancer (two subcategories), bowel cancer (five subcategories), prostate 
and breast cancers (Supplementary Table 1). Those participant who 
answered “not to know” or “prefer not to answer” when they were asked about 
the disease status of relatives were removed from the analyses. Disease 
  
status of sibling was only considered when participants reported to have one 
sibling since they just had to report if at least one sibling had the 
corresponding disease and it was not possible to know how many siblings had 
suffered the disease when participants had more than one sibling. Disease 
status of 470,640 participants, 464,302 blood mothers, 459,716 blood fathers, 
152,887 blood siblings, 4,962 adoptive mothers, 4,580 adoptive fathers and 
1,819 adoptive siblings were used in the analyses. Those participants 
declared to have “white”, “British”, “Irish” or “Other white” ethnic background. 
Medical Records 
Data from medical records were used to test the accuracy of ten self-reported 
diseases. The type of medical record used to define a disease was different 
depending on the disease and was chosen because it was considered to be 
the best indicator of the disease available. Supplementary Table 2 shows the 
categories used to define each disease. There were available three kinds of 
medical records in the UK Biobank: data of hospitalization, 
medication/treatment and cancer register. 
• Data of hospitalization. Summary of the distinct main diagnoses codes 
a participant has had recorded across all their episodes in hospital. 
Heart disease, stroke, bronchitis, diabetes and Parkinson’s and 
Alzheimer’s diseases were defined with records from this register. 
• Medication/treatment. Medication self-reported by the participant used 
to treat the disease. Hypertension, diabetes and depression were 
defined with records form this registers. 
• Cancer Register. Data from the UK Cancer Register was used to define 
the cancer diagnoses.  
Accuracy of self-reported data and family health status 
Accuracy of self-reported health status was evaluated estimating the 
sensitivity, specificity, positive (PPV), and negative (NPV) predictive values 
among self-reported data and medical records from cancer register, 
hospitalization records and medication. The sensitivity was estimated as the 
percentage of individuals who self-reported having a disease among all those 
  
who appeared in the corresponding register as ill or taking the medication for 
the disease analyzed, the specificity was calculated as the percentage of 
those who self-reported being healthy for a particular disease among those 
who did not appear in the corresponding register or did not report taking 
medication for the corresponding disease. Positive predictive value (PPV) is 
the percentage of individuals who appeared in the corresponding register or 
were taking medication for a particular disease among those who self-
reported having a disease, and the negative predictive value (NPV) is the 
proportion of those who did not appear in the registers or they did not report 
taking medication for the disease analyzed among those who did not report to 
have a particular disease. There were a total of 305,695 participants with 
hospitalization records that were used to estimate the accuracy of the self-
reported phenotypes.  
Prevalence 
Prevalence of diseases in the UK Biobank were estimated as the number of 
people found to have a disease divided by the total number of individuals 
studied and their standard errors (SE) were estimated using the following 
formula: 
SE = p(1-p)n  
where p is the prevalence and n is the total number of individuals studied. 
Relative Risks 
Relative risks of disease in the UK Biobank were estimated as follow21:  
 
RR = 
a
a+b
a+c
a+b+c+d
 
 
where a was the number of ill relatives of ill participants, b was the number of 
healthy relatives of ill participants, c was the number of ill relatives of healthy 
participants and d was the number of healthy relatives of healthy participants. 
  
The relative risk of parents (RRPO) and the relative risk of siblings (RRSIB) 
were estimated using this formula. The relative risks of partners, who are 
parents of participant, (RRPAR) was calculated in a similar way. The 95% 
confidence intervals (CI95%) were estimated as: 
CI95% = eloge (RR)±1.96s 
where RR is the corresponding relative risks and s is estimated as: 
 
s = a2+bca(a+b)(a+c) - 1a+b+c+d 
 
  
The minimum number of pairs in which both individuals are affected needed 
to estimate RR is one. In our dataset, the lowest number of pairs available to 
estimate RR was 33. 
Heritability estimates  
Diseases were treated as binary traits assumed to be determined by an 
underlying normal distribution of liability to disease. The correlation or 
regression among relatives (b) was used to estimate the heritability (h2 = 2b) 
of liability to disease. Method 4 described by Falconer1 was used to estimate 
b: 
 
b = 
pg (xc - xr )
αg
 
 
where pg is the prevalence of the disease in the relevant population within the 
UK Biobank, xc is the deviation of the threshold of liability that defines disease 
status from the mean of relatives of healthy participants, xr is the deviation of 
the threshold of liability that defines disease status from the mean of relatives 
of ill participants, and αg is the mean liability deviation of the ill participants 
from the mean liability of the relevant population within the UK Biobank. The 
sampling variance (Vb) of b was estimated according to appendix C of 
  
Falconer1 and confirmed by bootstrapping. The minimum number of pairs in 
which both individuals are affected needed to estimate b was one. In our data 
set the lowest number of pairs available to estimate b was three (in the 
adoptive pairs). 
Across generation differences in disease prevalence were taken into account 
using an appropriate control population for comparison. Since prevalences 
among genders were different, four estimates according gender pairs were 
estimated using this method, which allows controlling for differences in gender 
and age prevalence when the variance in mean liability is different. The 
following sets of relatives were used: parent-offspring, sib-sib and parent-sib 
of participants (blood and adoptive) except for prostate and breast cancers 
where we only estimated same gender correlations. Moreover, b was 
estimated among the parents of the participants. For each relationship class, 
the correlations or regressions obtained from the four gender-parings were 
combined into a single weighted mean (bw), the weight being the reciprocal of 
the sampling variance of each regression coefficient. The sampling variance 
(Vbw) was calculated as the reciprocal of the sum of the weights and the 
standard error of the heritability was obtained as the square root of 4Vbw. 
Genetic correlation 
Genetic correlation (rG) between sexes was calculated for all the diseases 
except for prostate cancer and breast cancer which are expressed mostly in 
one sex. The following formula was used22: 
 
rG =   (bFEMALE-MALEbMALE-FEMALE)/(bFEMALE-FEMALEbMALE-MALE) 
 
where bFEMALE-MALE is the regression/correlation of mother-son or sister-brother 
bMALE-FEMALE, the regression/correlation of father-daughter or brother-sister, 
bFEMALE-FEMALE, the regression/correlation of mother-daughter or sister-sister 
and  bMALE-MALE the regression/correlation of father-son or brother-brother.  
 
Liability components  
  
The liability to disease is the sum of genetic and different environmental 
effects. The distribution of the liability has a threshold value which 
differentiates between healthy and ill individuals. This threshold is based on 
the prevalence of the disease. As the prevalences are different in parents, 
siblings and participants, different thresholds must be assumed.  
To estimate the liability parameters we can define the following structural 
equation: 
L = A + C + S + P + E 
where, A are genetic effects (assumed additive in the liability scale)23; C are 
environmental effects shared in common by all family members; S are 
environmental effects shared by siblings but not their parents which may 
include non-additive genetic effects; P are environmental effects shared 
among parents of participant (i.e. among partners) but not their children; and 
E are residual effects (including environmental effects specific to an individual 
and measurement error).  
The correlations between each pair of blood and adoptive relatives for genetic 
and environmental components are set to fixed values according to their 
degree of genetic and environmental relationship. For example, blood 
parents-offspring pairs are correlated 0.5 for the genetic factors and 1 for 
common environmental effects. All the corresponding correlation values are 
shown in the Supplementary Figure 2. The relative importance of these 
components was evaluated using structural equation models (SEM) using 
OpenMx software version 1.4-353224. 
Data of 210,787 blood and 4,184 adoptive families with one or two offspring 
(i.e. the participant and one sibling) were used to estimate liability 
components. A full model including all the effects (ACSPE) and all reduced 
models including genetic effects but removing one or more environmental 
effects were fitted. Each model was run 1,000 times and the run that 
converged with the maximum likelihood was chosen for model comparison. 
The relative fit of nested models was compared using hierarchic chi-square 
  
tests because the difference between the likelihood for a reduced model and 
that for the full model is approximately distributed, as a chi-square with df = 
df(full model) - df(reduced model). For each disease we started with the 
simplest model and included more parameters until we obtained the most 
parsimonious but adequate model that did not fit the data significantly worse 
than the full model. 
Simulations 
We simulated pedigrees with the same structure of families as in the real data 
comprising 210,787 blood and 4,184 adoptive families. To simulate the 
diseases, the prevalences of each disease in fathers, mothers, participant and 
siblings were used together with the parameters obtained using the full model 
(Supplementary Table 8). The full model was fitted using OpenMx following 
the same procedure as with real data. Analyses with 10 simulation replicates 
for each disease were performed to estimate liability parameters. The means 
and standard deviations of the 10 replicates for each of the liability 
components were estimated. Model comparison for each replicate was carried 
out in the same way as with real data. 
Genotype Quality Control  
We use data from the genotyped individuals in phase 1 of the UK Biobank 
genotyping program. In this phase, 49,979 individuals were genotyped using 
the Affymetrix UK BiLEVE Axiom array and 102,750 individuals using the 
Affymetrix UK Biobank Axiom array. Further details regarding genotyping 
procedure and genotype calling protocols are available at the UK Biobank 
website. We excluded multi-allelic markers, SNPs with an overall missing rate 
higher than 2% or with a strong platform specific missing bias (Fisher’s exact 
test, P < 10-100). We also excluded individuals with a missing rate higher than 
5%, with a self-reported sex different from the genetic sex estimated from the 
X chromosome inbreeding or those with an excess of heterozygosity 
according to the UK Biobank internal QC procedures. 
  
A reduced dataset of 151,532 individuals remained after filtering. In addition to 
this, common and rare variants (i.e. with a MAF > 0.0036) and those that did 
not exhibit departure from Hardy-Weinberg equilibrium (P < 10-50) in the 
unrelated (subset of 114,264 individuals with a relatedness below 0.0625) 
White-British cohort were kept. The genotype quality control and data filtering 
was performed using plink25. 
SNP heritability estimates 
SNP heritability estimates were estimated in a subset of 114,264 individuals 
for nine out of the twelve diseases with a prevalence in the population higher 
than 0.50% (heart disease, stroke, chronic bronchitis, hypertension, diabetes, 
severe depression and bowel, prostate and breast cancers) using self-
reported data and medical records. 
To estimate the heritability for each disease and data set, the genetic 
relationship matrices (GRMs) were computed fitting simultaneously 525,242 
SNPs in the following mixed lineal model: 
y=Xβ+Wu+ϵ 
 
where y is the vector of phenotypes (diseases), β is the vector of fixed effects 
and covariates which included age of participant, the 20 first principal 
components and gender (except for prostate and breast cancer), u is the 
vector of SNP effects distributed as u∼N(0,I ,u2), I is the identity matrix, and ϵ is 
a vector of residual effects distributed as ϵ∼N(0,Iσ!2). W is a genotype matrix 
defined by the equation: 
 
Wik= 
(sik-2pk)
2pk (1-pk)
 
 
where sik is the number of copies of the reference allele for the SNP k of the 
individual i, and pk is the frequency of the reference allele for the SNP k. 
Under this model, the variance of y is: 
     
var y =Aσg2+Iσϵ2 
  
Where A is the GRM, σ2g the genetic variance and σ2ε the residual variance. 
Variance components were estimated using restricted maximum likelihood 
(REML). These analyses were performed using DISSECT26.  
In addition to this, a two variance component model splitting the SNPs into 
319,037 common SNPs (MAF>0.05) and 206,205 rare SNPs 
(0.0036<MAF<0.05) was fitted for each disease.  
y=Xβ+Wcommonucommon+Wrareurare+ϵ 
where, ucommon and urare  are the vectors of SNP effects for common and rare 
variants, respectively. Wcommon and Wrare are the genotype matrices defined for 
common and rare variants, respectively. 
Under this model, the variance of y is: 
var y =Acommonσgcommon
2 +Arareσgrare
2 +Iσϵ2 
where Acommon and the Arare are the GRMs computed using the common and 
rare variants, respectively. σ2gcommon and σ2grare are the genetic variances 
explained by the common and rare variants, respectively. 
The heritability estimates were transformed to the liability scale using the 
following equation:  
hL2= h 0,12  
P(1-P)
Z2 
  
 
where h2L is the heritability in the liability scale is the heritability in the liability 
scale h2(0,1) is the heritability in the observed scale obtained from the REML 
analyses, P is the prevalence of the disease in the cohort and Z is the height 
of the standard normal probability density function at the threshold that 
truncates the proportion P23.  
The percentage of SEM family-based estimates of heritability explained by 
SNPs was calculated as the ratio between h2SNPs and h2SEM multiplied by 100 
and the standard error of the percentage was calculated according to Stuart et 
al27 as: 
 
  
SE(%) = hC+RSNPs
2
hSEM2
2 σ
hC+RSNPs
2
2
hC+RSNPs4
+ 
σ
hSEM
2
2
hSEM4
- 2COV C+RSNPs,SEM
hC+RSNPs 2 hSEM2
 x 100  
where h2C+RSNPS is the heritability explained by common and rare SNPs, h2SEM 
is the heritability using SEM family-based, σ2h2C+RSNPs is the standard 
deviation of h2C+RSNPS, σ2h2SEM is the standard deviation of h2SEM, C+RSNPs 
are related to the distribution of the estimates of h2C+RSNPS and SEM related to 
the distribution of the estimates of h2SEM. We cannot estimate 
2COV C+RSNPs,SEM  and assume this value is equal to 0. 
Testing of GWAS hits for self-reported and clinical definitions of 
disease 
GWAS hits for breast cancer, prostate cancer, bowel cancer, Type 2 diabetes, 
Hypertension, Stroke and Cardiovascular Artery Disease were downloaded 
from the GWAS catalogue. In total, we found that 278 of these SNPs were 
genotyped in our array, and tested them for association with our self-reported 
and clinical definitions of disease (breast cancer, prostate cancer, bowel 
cancer, Type 2 diabetes, Hypertension, Stroke and Heart Disease) using a 
chi-square test as implemented in the plink2 option (--assoc)25. Significant 
SNPs at a p-value of 0.05 and 0.00018 (i.e. 0.05/278) were counted for the 
two definitions of disease (self-reported and clinical). Only the subset of 
genotyped samples with clinical information was used to compare the power 
of the two alternative phenotype definitions. 
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Supplementary note 
Accuracy of self-reported data 
The accuracy of self-reported health status was evaluated estimating the sensitivity, 
specificity, positive (PPV), and negative predictive values (NPV) among self-reported 
data and medical records from cancer register, hospitalization records and 
medication (Supplementary Tables 2 and 3). Specificity and NPV were 1 or close to 
1 for all the diseases pointing out a negligible number of false negatives. Sensitivity 
and PPV was higher than 0.70 for all the cancer diseases and for hypertension and 
diabetes suggesting a high percentage of true positives. However, lower values of 
sensitivity and PPV were observed for heart disease, stroke, bronchitis and 
depression.  
The cancer register is likely to be the most reliable database which likely captures 
the majority the cancers diagnosed in UK, however hospitalization records or 
medication may not contain all the cases, especially for less well recorded diseases. 
For instance, patients could be diagnosed with bronchitis but never have been 
hospitalized. In addition to this, a participant of the UK Biobank could report an 
episode of depression in the past and he/she could not report taking medication for 
this disease as would be already recovered from the disease when recruited. 
Therefore the cancer register data is likely to be the most complete data set, whilst 
hospitalization and medication information is potentially incomplete. Given the 
accuracy of the self-reported data for cancer and the fact that medical history was 
confirmed by a trained nurse and where necessary by a medical doctor, it suggests 
that the self-reported data may too be of high quality. 
Furthermore, self-reported data and medical records provided very similar estimates 
of SNP heritability for the nine diseases for which we estimated SNP heritabilities 
(Table 3 - Figure 1). 
 
  
Supplementary Table 1. Different categories of disease in participants and 
their corresponding disease in relatives. 
Relative disease Participant disease 
Heart disease 
Heart Cardiac Problem 
Angina 
Heart attack/Myocardial infarction 
Heart failure/Pulmonary oedema 
Heart arrhythmia 
Atrial fibrillation 
Atrial flutter 
Wolf Parkinson White/wpw synd 
Irregular heart beat 
Sick sinus syndrome 
Svt/Supraventricular tachycardia 
Heart valve problem/heart murmur  
Mitral Valve disease 
Mitral Valve prolapse 
Mitral stenosis 
Mitral regurgitation 
Aortic valve disease 
Aortic stenosis 
Aortic regurgitation 
Cardiomyopathy 
Hypertrophic card 
Pericardial Problem 
Pericarditis 
Pericardial effusion 
Myocarditis 
Rheumatic Fever 
Stroke 
Stroke 
Subarachnoid Haemorrhage 
Ischaemic Haemorrhage 
Brain Haemorrhage 
Chronic 
bronchitis/emphysema 
Emphysema/Chronic Bronchitis 
Bronchitis 
Emphysema 
Alpha-1 Antitrypsin Deficiency 
High blood pressure 
Hypertension 
Essential Hypertension 
Gestational Hypertension/Preclampsia 
Diabetes 
Diabetes 
Gestational Diabetes 
Type 1 Diabetes 
Type 2 Diabetes 
Diabetes insipidus 
Alzheimer's 
disease/dementia 
Dementia/Alzheimer/Cognitive Impairment 
Parkinson's disease Parkinson’s disease 
Severe depression Severe depression 
Lung cancer 
Lung Cancer 
Small cell lung cancer 
Non-small cell lung cancer 
Bowel cancer 
Bowel cancer 
Small bowel cancer 
Large bowel cancer/colorectal cancer 
Colon Cancer/Sigmoid cancer 
Appendix cancer 
Rectal cancer 
Prostate cancer Prostate cancer 
Breast cancer Breast cancer 
 
 
 
 
 
Supplementary Table 2. Medical records used to evaluate accuracy of self-
reported data. 
Self –reported disease Medical Record Numbe
r 
Heart disease 
Cardiac arrhythmias  9,676 
Myocardial Infarction 6,573 
Angina pectoris 5,452 
Heart failure  2,943 
Non-rheumatic valve disorders  2,855 
Cardiomyopathy  655 
Acute pericarditis  549 
Other ill-defined heart diseases 429 
Pulmonary oedema  328 
Heart disease, unspecified  189 
Myocarditis  27 
Acute rheumatic fever  14 
 Stroke 
Cerebral infarction  1,855 
Stroke, not specified as haemorrhage or infarction  918 
Sequelae of cerebrovascular disease  828 
Occlusion and stenosis of precerebral arteries, not 
resulting in cerebral infarction  
667 
Subarachnoid haemorrhage  656 
Intracerebral haemorrhage  433 
Cerebrovascular disease, unspecified  579 
Other non-traumatic intracranial haemorrhage  223 
Occlusion and stenosis of cerebral arteries, not 
resulting in cerebral infarction  
30 
Chronic 
bronchitis/emphysema 
Simple and mucopurulent chronic bronchitis  899 
Bronchitis, not specified as acute or chronic  421 
Emphysema  186 
Unspecified chronic bronchitis  14 
High blood pressure 
Ramipril 21,885 
Amlodipine  19,074 
Atenolol 18,378 
Bisoprolol 6,915 
Perindopril 6,748 
Candesartan cilexetil 5,027 
Losartan 4,271 
Felodipine 3,961 
Enalapril 3,597 
Irbesartan 3,345 
Propranolol 3,137 
Lercanidipine 1,137 
Diltiazem 954 
Metoprolol 898 
Verapamil 789 
Telmisartan 738 
Sotalol 728 
Olmesartan 549 
Lacidipine 490 
Losartan Potassium+Hydrochlorothiazide 
50mg/12.5mg Tablet 
373 
Bisoprolol Fumarate+Hydrochlorothiazide 
10mg/6.25mg Tablet 
299 
Eprosartan 273 
Trandolapril 271 
Captopril  206 
Quinapril 204 
Irbesartan+Hydrochlorothiazide 150mg/12.5mg Tablet 109 
Valsartan+Hydrochlorothiazide 80mg/12.5mg Tablet 71 
Atenolol+bendroflumethiazide 59 
Nicardipine 57 
Propranolol Hydrochloride+Bendrofluazide 
80mg/2.5mg Capsule 
51 
Sotalol Hydrochloride+Hydrochlorothiazide 
80mg/12.5mg Tablet 
38 
Atenolol+bendrofluazide 27 
Cilazapril 22 
Metoprolol Tartrate+Chlorthalidone 100mg/12.5mg 
Tablet 
22 
Acebutolol  18 
Oxprenolol 16 
Pindolol 12 
Atenolol+chlorthalidone 10 
Atenolol+chlortalidone 8 
Atenolol+Nifedipine 50mg/20mg M/R Capsule 5 
Timolol Maleate+Bendrofluazide 10mg/2.5mg Tablet 5 
Metoprolol Tartrate+Hydrochlorothiazide 
100mg/12.5mg Tablet 
4 
Captopril+Hydrochlorothiazide 25mg/12.5mg Tablet 2 
Atenolol+co-amilozide 3 
Timolol Maleate+Co-Amilozide 10mg/2.5mg/25mg 
Tablet 
3 
Diabetes 
Type 2 diabetes 13,408 
Other specified diabetes mellitus 2,630 
Insulin product 563 
Type 1 diabetes 366 
Pioglitazone 206 
Rosiglitazone 140 
Glucophage 500mg tablet 110 
Unspecified diabetes mellitus 107 
Glimepiride 68 
Actos 15mg tablet 15 
Repaglinide 13 
Nateglinide 12 
Avandia 4mg tablet 11 
Amaryl 1mg tablet 5 
Glipizide product 1 
Alzheimer’s Disease Alzheimer’s Dementia 90 
Parkinson’s Disease Parkinson’s Disease 569 
Severe depression Amitriptyline 8,968 
Citalopram 8,063 
Fluoxetine 5,502 
Sertraline 1,986 
Venlafaxine 1,917 
Paroxetine 1,591 
Prozac 20mg Capsule 644 
Seroxat 20mg Tablet 627 
Duloxetine 403 
Clomipramine 315 
Nortriptyline 277 
Lofepramine 273 
Efexor 37.5mg Tablet 242 
Imipramine 240 
Cipramil 10mg Tablet 162 
Amitriptyline Hydrochloride+Perphenazine 10mg/2mg 
Tablet 
110 
Lustral 50mg Tablet 66 
Cymbalta 30mg Gastro-Resistant Capsule 43 
Anafranil 10mg Capsule 39 
Phenelzine 31 
Moclobemide 28 
Yentreve 20mg Gastro-Resistant Capsule 28 
Allegron 10mg Tablet 6 
Nardil 15mg Tablet 4 
Gamanil 70mg Tablet 2 
Manerix 150mg Tablet 2 
Tofranil 10mg Tablet 1 
Amitriptyline+Chlordiazepoxide 12.5mg/5mg Capsule 1 
Tryptizol 10mg Tablet 1 
Lung cancer 
Malignant neoplasm of bronchus and lung 281 
Neoplasma Trachea, bronchus and lung 31 
Neoplasm of pleura 2 
Secondary malignant neoplasm of lung 1 
Bowel cancer 
Malignant neoplasm of colon 1,390 
Malignant neoplasm of rectum 1,072 
Neoplasm of uncertain behaviour 186 
Malignant neoplasm of small intestine 55 
Carcinoma in situ of rectum 38 
Carcinoma in situ of colon 35 
Benign neoplasm of colon, rectum, anus and anal 
canal 
5 
Carcinoma in situ of rectosigmoid junction 3 
Prostate cancer Carcinoma in situ of prostate 3,126 
Malignant neoplasm of prostate 169 
Neoplasm of uncertain behavior of prostate 9 
Breast cancer Malignant neoplasm of breast 7,589 
Carcinoma in situ of breast 1,197 
Neoplasm of uncertain or unknown behaviour breast 29 
 
 
 
Supplementary Table 3. Sensitivity, specificity, positive (PPV) and negative (NPV) predictive values among self-reported 
data and medical record used. 
Disease Medical 
Records 
Sensitivity (CI95%) Specificity 
(CI95%) 
PPV (CI95%) NPV (CI95%) 
Heart Disease Hospitalization 0.65 (0.64-0.65) 0.97 (0.97-0.97) 0.72 (0.71-0.72) 0.96 (0.96-0.96) 
Stroke Hospitalization 0.55 (0.54-0.57) 0.99 (0.99-0.99) 0.42 (0.41-0.44) 0.99 (0.99-0.99) 
Bronchitis Hospitalization 0.43 (0.41-0.44) 0.98 (0.98-0.98) 0.15 (0.14-0.16) 1.00 (1.00-1.00) 
Hypertension Medication 0.86 (0.85-0.87) 0.90 (0.90-0.90) 0.71 (0.71-0.71) 0.96 (0.96-0.96) 
Diabetes Hospitalization & 
Medication 
0.85 (0.84-0.86) 0.98 (0.98-0.98) 0.72 (0.71-0.73) 0.99 (0.99-0.99) 
Alzheimer’s Hospitalization 0.14 (0.09-0.18) 1.00 (1.00-1.00) 0.22 (0.15-0.30) 1.00 (1.00-1.00) 
Parkinson’s Hospitalization 0.75 (0.72-0.79) 1.00 (1.00-1.00) 0.67 (0.63-0.70) 1.00 (1.00-1.00) 
Depression Medication 0.52 (0.51-0.52) 0.98 (0.98-0.98) 0.63 (0.62-0.64) 0.97 (0.96-0.97) 
Lung cancer Cancer Register 0.83 (0.79-0.87) 1.00 (1.00-1.00) 0.70 (0.65-0.74) 1.00 (1.00-1.00) 
Bowel cancer Cancer Register 0.83 (0.82-0.85) 1.00 (1.00-1.00) 0.85 (0.83-0.86) 1.00 (1.00-1.00) 
Prostate cancer Cancer Register 0.91 (0.90-0.92) 1.00 (1.00-1.00) 0.91 (0.90-0.92) 1.00 (1.00-1.00) 
Breast cancer Cancer Register 0.97 (0.97-0.97) 1.00 (1.00-1.00) 0.94 (0.94-0.95) 1.00 (1.00-1.00) 
CI95%: Confidence intervals. 
 
 
Supplementary Table 4. Prevalence percentages and standard errors of the analysed diseases in the UK Biobank.  
 Prevalence % (SE) 
Disease  Participants Men Women Parents Fathers Mothers Siblings Brothers Sisters 
Heart Disease 7.19 (0.04) 10.09 (0.06) 4.77 (0.04) 23.91 (0.04) 29.09 (0.07) 18.72 (0.06) 4.86 (0.05) 6.99 (0.09) 2.56 (0.06) 
Stroke 1.45 (0.02) 1.86 (0.03) 1.10 (0.02) 13.51 (0.04) 13.72 (0.05) 13.30 (0.05) 1.42 (0.03) 1.09 (0.04) 1.73 (0.05) 
Bronchitis 2.16 (0.02) 2.34 (0.03) 2.01 (0.03) 7.86 (0.03) 10.17 (0.04) 5.54 (0.03) 1.30 (0.03) 1.40 (0.04) 1.20 (0.04) 
Hypertension 26.63 (0.06) 30.29 (0.10) 23.57 (0.08) 24.17 (0.04) 19.85 (0.06) 28.50 (0.07) 13.94 (0.09) 13.47 (0.13) 14.37 (0.12) 
Diabetes 4.71 (0.03) 6.48 (0.05) 3.23 (0.03) 8.57 (0.03) 8.41 (0.04) 8.72 (0.04) 4.21 (0.05) 5.05 (0.08) 3.30 (0.07) 
Alzheimer’s 0.02 (0.002) 0.03 (0.01) 0.02 (0.01) 6.10 (0.02) 4.21 (0.03) 7.99 (0.04) 0.21 (0.01) 0.19 (0.02) 0.24 (0.02) 
Parkinson’s 0.17 (0.01) 0.24 (0.01) 0.12 (0.01) 1.87 (0.01) 2.21 (0.02) 1.53 (0.02) 0.24 (0.01) 0.32 (0.02) 0.16 (0.01) 
Depression 5.71 (0.03) 4.28 (0.04) 6.90 (0.05) 4.77 (0.02) 3.35 (0.03) 6.19 (0.04) 4.17 (0.05) 4.59 (0.08) 3.78 (0.07) 
Lung cancer 0.09 (0.01) 0.11 (0.01) 0.07 (0.01) 6.02 (0.02) 8.19 (0.04) 3.86 (0.03) 0.77 (0.02) 0.92 (0.03) 0.61 (0.03) 
Bowel cancer 0.58 (0.01) 0.71 (0.02) 0.46 (0.01) 5.05 (0.02) 5.24 (0.03) 4.85 (0.03) 0.99 (0.03) 1.08 (0.04) 0.89 (0.03) 
Prostate cancer - 1.54 (0.03) - - 6.79 (0.05) - - 1.49 (0.04) - 
Breast cancer 2.31 (0.02) 0.02 (0.01) 4.22 (0.04) - - 7.85 (0.04) 2.17 (0.04) 0.04 (0.01) 4.47 (0.08) 
SE: Standard errors; -: There were not data for the corresponding disease. 
 
 
Supplementary Table 5. Genetic correlations among genders. 
Illness rGPO (SE) rGSIB (SE) 
Heart Disease 0.81 (0.01) 0.90 (0.01) 
Stroke 0.78 (0.02) 1.24 (0.57) 
Bronchitis 0.87 (0.01) 0.80 (0.05) 
Hypertension 0.78 (0.01) 0.95 (0.01) 
Diabetes 0.93 (0.01) 0.92 (0.01) 
Alzheimer’s 0.83 (0.07) - 
Parkinson’s 1.03 (0.01) - 
Depression 0.96 (0.01) 0.93 (0.02) 
Lung cancer 2.40 (1.34) - 
Bowel cancer 0.73 (0.02) 0.99 (0.01) 
rGPO: Genetic correlations using parent-offspring pairs;  
rGSIB: Genetic correlation using sibling pairs. SE: Standard errors, 
-: There was no pair with the two members affected to estimate the genetic 
correlation 
 
 
 
 
 
 
 
 
 
 
 
 Supplementary Table 6. Heritability estimates from published twin studies. 
Disease h2 (CI95%) Study§ 
Heart Disease 
0.39 (0.29-0.49)   Zdravkovic et al. (2007) 
0.43 (0.08-0.51)   
Stroke 0.41 (0.24-0.56) Korja et al. (2010) 
Bronchitis 
0.40 (0.33–0.47)   Hallberg et al.  (2007) 
0.38 (0.12–0.47)   
Hypertension 0.39 (0.2 – 0.5) DBP 
0.52 (0.37 – 0.65) SBP 
Iliadou et al. (2002) 
Diabetes 0.64¥ Kaprio et al. (1992) 
Alzheimer’s 0.79 (0.67-0.88) Gatz et al. (2006) 
Parkinson’s 0.36 (0.28-0.44)   Polderman et al. (2015) 
Depression 0.37 (0.33-0.42) Sullivan et al. (2010) 
Lung cancer 0.26 (0.00–0.49) Lichtenstein et al. (2010) 
Bowel cancer 0.35 (0.10–0.48) Lichtenstein et al. (2010) 
Prostate cancer 0.42 (0.29–0.50) Lichtenstein et al. (2010) 
Breast cancer 0.27 (0.04–0.41) Lichtenstein et al. (2010) 
h2: Heritability estimates; (CI95%): Confidence intervals; § Studies cited in main text 
and bibliography;  : Males;  : Females ¥ Confidence intervals not shown in the 
paper.  
 
 
 
 
 
 
 
  
Supplementary Table 7. Genetic and environmental effects estimated using 
the full and parsimonious reduced SEM models.  
Disease Model LL p-value A C S P E 
Heart Disease ACSPE 1669870.83¥ <0.05* 0.27 0.08 0.08 0.06 0.51 
Stroke ACSPE 1048621.32 0.16 0.23 0.00 0.05 0.04 0.69 APE 1048624.91 0.23 - - 0.04 0.73 
Bronchitis ACSPE 739568.10 0.24 0.29 0.10 0.03 0.00 0.59 ACE 739570.99 0.29 0.10 - - 0.61 
Hypertension ACSPE 2278607.50¥ <0.05* 0.28 0.06 0.14 0.13 0.39 
Diabetes ACSPE 1002661.33 0.60 0.47 0.02 0.11 0.05 0.35 ASPE 1002661.60 0.50 - 0.11 0.07 0.32 
Alzheimer’s ACSPE 558921.77 1 0.28 0.03 0.03 0.01 0.65 ACE 558921.21 0.25 0.05 - - 0.70 
Parkinson’s ACSPE 252436.39 0.37 0.20 0.03 0.05 0.00 0.72 AE 252439.54 0.26 - - - 0.74 
Depression ACSPE 839646.58 1 0.25 0.15 0.00 0.00 0.60 ACE 839646.58 0.25 0.15 - - 0.60 
Lung cancer ACSPE 522617.83 0.71 0.21 0.05 0.05 0.06 0.64 ACE 522618.49 0.09 0.11 - - 0.81 
Bowel cancer ACSPE 544144.54 1 0.23 0.03 0.06 0.00 0.68 ACSE 544144.54 0.24 0.03 0.06 - 0.67 
Prostate cancer ACSE 98725.19 1 0.38 0.00 0.19 - 0.43 ASE 98725.19 0.38 - 0.19 - 0.43 
Breast cancer ACSE 204255.53 1 0.29  0.00 0.06 - 0.65 ASE 204255.53 0.29 - 0.06 - 0.65 
LL: -2log likelihood; ¥ for heart disease and hypertension only the full model is shown 
because it was the most parsimonious; p-value corresponding to the difference 
between LL, for heart disease and hypertension the p-value was always lower than 
0.05 for all the comparisons; *all the reduced models were significantly worse than 
the full one; A: Additive genetic effects; C: Environmental effects common to the 
whole family; S: Sibling environmental effects; P: Partner environmental effects; E: 
Residual environmental effect; 
-: effect not included in the model 
 
 
 
Supplementary Table 8. Parameters used in the simulations of disease. 
Disease Model 
Liability components Prevalences 
A C S P E Father Mother Participant Sibling 
Heart Disease ACSPE 0.27 0.08 0.08 0.06 0.51 0.291 0.187 0.0719 0.049 
Stroke ASPE 0.23 0.00 0.05 0.04 0.69 0.137 0.133 0.0145 0.014 
Bronchitis ACSE 0.29 0.10 0.03 0.00 0.59 0.102 0.055 0.0216 0.013 
Hypertension ACSPE 0.28 0.06 0.14 0.13 0.39 0.199 0.285 0.2663 0.139 
Diabetes ACSPE 0.47 0.02 0.11 0.05 0.35 0.084 0.087 0.0471 0.042 
Alzheimer’s ACSPE 0.28 0.03 0.03 0.01 0.65 0.042 0.080 0.0002 0.002 
Parkinson’s ACSE 0.20 0.03 0.05 0.00 0.72 0.022 0.015 0.0017 0.002 
Depression ACE 0.25 0.15 0.00 0.00 0.60 0.034 0.062 0.0570 0.042 
Lung cancer ACSPE 0.21 0.05 0.05 0.06 0.64 0.082 0.039 0.0009 0.008 
Bowel cancer ACSE 0.23 0.03 0.06 0.00 0.68 0.052 0.049 0.0058 0.010 
Prostate cancer ASE 0.38 0.00 0.19 - 0.43 0.068 - 0.0154 0.015 
Breast cancer ASE 0.29  0.00 0.06 - 0.65 - 0.079 0.0422 0.045 
A: Additive genetic effects; C: Environmental effects common to the whole family; S: Sibling environmental effects; P: Partner 
environmental effects; E: Residual environmental effect; -: effect not included in the model or prevalence not estimated because the 
disease is limited to one sex 
 
 
Supplementary Table 10. Number of simulation replicates where the SEM recovers the model used to simulate data, and 
mean and standard deviation of the parameter estimates.  
Diseases Model Replicates A C S P E 
Heart Disease ACSPE 5 0.29 (0.02) 0.08 (0.01) 0.08 (0.01) 0.06 (0.01) 0.48 (0.02) 
Stroke ASPE 4 0.26 (0.01) - 0.06 (0.02) 0.04 (0.01) 0.65 (0.01) 
Bronchitis ACSE 1 0.33 (ne) 0.08 (ne) 0.04 (ne) - 0.55 (ne) 
Hypertension ACSPE 8 0.32 (0.04) 0.07 (0.02) 0.16 (0.00) 0.15 (0.02) 0.30 (0.03) 
Diabetes ACSPE 0 - - - - - 
Alzheimer’s ACSPE 0 - - - - - 
Parkinson’s ACSE 0 - - - - - 
Depression ACE 10 0.25 (0.02) 0.15 (0.01) - - 0.60 (0.01) 
Lung cancer ACSPE 0 - - - - - 
Bowel cancer ACSE 2 0.25 (0.01) 0.03 (0.01) 0.08 (0.01) - 0.64 (0.01) 
Prostate cancer ASE 10 0.43 (0.03)  0.16 (0.02) - 0.41 (0.03) 
Breast cancer ASE 3 0.30 (0.02) - 0.08 (0.02) - 0.62 (0.04) 
SD: Between brackets; ne: non-estimable; - not recovered parameter 
 
 
 
 
 
 
Supplementary Table 11. Number of simulation replicates where the SEM does not recover the model used to simulate 
data, and the mean and standard deviation of the parameter estimates.  
Diseases Replicates A C S P E 
Heart Disease 5 0.28 (0.16) 0.09 (0.08) 0.09 (0.00) 0.06 (0.08) 0.48 (0.16) 
Stroke 6 0.25 (0.01) 0 (0.00) 0 (0.00) 0.04 (0.01) 0.71 (0.02) 
Bronchitis 9 0.41 (0.11) 0.05 (0.05) 0 (0.00) 0.06 (0.05) 0.49 (0.11) 
Hypertension 2 0.46 (0.00) 0 (0.00) 0.16 (0.00) 0.22 (0.01) 0.17 (0.01) 
Diabetes 10 0.53 (0.05) 0.01 (0.03) 0.11 (0.01) 0.08 (0.03) 0.28 (0.05) 
Alzheimer’s 10 0.32 (0.07) 0.02 (0.02) 0 (0.00) 0.03 (0.02) 0.64 (0.07) 
Parkinson’s 10 0.27 (0.02) 0 (0.00) 0 (0.00) 0.01 (0.03) 0.73 (0.04) 
Depression 0 - - - - - 
Lung cancer 10 0.07 (0.03) 0.12 (0.01) 0.08 (0.09) - 0.72 (0.08) 
Bowel cancer 8 0.30 (0.01) 0.00 (0.01) 0.02 (0.04) 0.02 (0.02) 0.66 (0.05) 
Prostate 
cancer 
0 - - - - - 
Breast cancer 7 0.30 (0.02) 0 (0.00) 0 (0.00) - 0.70 (0.02) 
SD: Between brackets; - not recovered parameter 
 
 
Supplementary Table 9. Mean of parameter estimates from SEM under the full 
model of the ten replicates for each disease simulated. 
Diseases A C S P E 
Heart Disease 0.28 (0.06) 0.09 (0.03) 0.08 (0.01) 0.06 (0.03) 0.48 (0.05) 
Stroke 0.24 (0.03) 0.00 (0.01) 0.05 (0.02) 0.04 (0.02) 0.67 (0.04) 
Bronchitis 0.37 (0.08) 0.06 (0.04) 0.03 (0.01) 0.03 (0.04) 0.51 (0.08) 
Hypertension 0.34 (0.05) 0.06 (0.02) 0.16 (0.01) 0.16 (0.02) 0.28 (0.05) 
Diabetes 0.53 (0.03) 0.01 (0.02) 0.11 (0.01) 0.07 (0.02) 0.28 (0.04) 
Alzheimer’s 0.33 (0.05) 0.01 (0.02) 0.06 (0.07) 0.03 (0.02) 0.57 (0.10) 
Parkinson’s 0.25 (0.02) 0.00 (0.01) 0.03 (0.04) 0.04 (0.03) 0.68 (0.05) 
Depression 0.28 (0.04) 0.13 (0.02) 0.01 (0.01) 0.02 (0.02) 0.56 (0.04) 
Lung cancer 0.12 (0.06) 0.09 (0.03) 0.12 (0.07) 0.03 (0.03) 0.64 (0.09) 
Bowel cancer 0.29 (0.03) 0.01 (0.01) 0.06 (0.06) 0.03 (0.03) 0.62 (0.04) 
Prostate cancer 0.25 (0.19) 0.09 (0.09) 0.15 (0.03) - 0.51 (0.09) 
Breast cancer 0.23 (0.06) 0.03 (0.03) 0.05 (0.03) - 0.69 (0.04) 
SD: Between brackets, -: effect not included in the model or prevalence not 
estimated because the disease is limited to one sex 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Table 12. Mean of parameter estimates from SEM of the AE 
model of the ten replicates for each disease simulated under the full model. 
Diseases A E 
Heart Disease 0.48 (0.01) 0.52 (0.01) 
Stroke 0.25 (0.01) 0.75 (0.01) 
Bronchitis 0.50 (0.01) 0.50 (0.01) 
Hypertension 0.51 (0.01) 0.49 (0.01) 
Diabetes 0.58 (0.01) 0.42 (0.01) 
Alzheimer’s 0.36 (0.03) 0.64 (0.03) 
Parkinson’s 0.26 (0.02) 0.74 (0.02) 
Depression 0.55 (0.01) 0.45 (0.01) 
Lung cancer 0.31 (0.03) 0.69 (0.03) 
Bowel cancer 0.31 (0.02) 0.69 (0.02) 
Prostate cancer 0.48 (0.03) 0.52 (0.03) 
Breast cancer 0.31 (0.02) 0.67 (0.10) 
SD: Between brackets 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Table 13. . Genetic and environmental effects estimated using 
the AE model in the UK Biobank data. 
Disease A  E  
Heart Disease 0.44  0.56  
Stroke 0.23  0.77  
Chronic Bronchitis 0.48  0.52  
Hypertension 0.45  0.55  
Diabetes 0.54  0.46  
Alzheimer’s 0.35  0.65  
Parkinson’s 0.26  0.74  
Depression 0.55  0.45  
Lung cancer 0.30  0.70  
Bowel cancer 0.30  0.70  
Prostate cancer 0.43  0.56  
Breast cancer 0.31  0.69  
 
 
 
Supplementary Table 14. Heritability estimates of the self-reported data when modelling all SNPs in a single variance 
component (C+R), or splitting common SNPs and rare SNP to estimate two variance components simultaneously. 
Disease h2C+R (CI95%)L h2C (CI95%)L h2R (CI95%)L %h2C+R/h2SEM (SE ) %(h2C+ h2R)/h2SEM (SE ) 
Heart Disease 0.114 (0.084-0.145) ¥ 0.088 (0.064-0.111)¥ 0.007 (0.000-0.035) 40.74 (9.79) 35.21 (77.02) 
Stroke 0.086 (0.004-0.168) ¥ 0.043 (0.000-0.095)  0.026 (0.000-0.092) 39.13 (29.07) 30.07 (37.20) 
Bronchitis 0.159 (0.097-0.221) ¥ 0.149 (0.091-0.208) ¥ 0.011 (0.000-0.077) 54.43 (15.72) 55.48 (25.12) 
Hypertension 0.321 (0.302-0.339) ¥ 0.261 (0.245-0.277)¥ 0.026 (0.010-0.042)¥ 114.29 (3.29) 102.50 (6.26) 
Diabetes 0.346 (0.304-0.387) ¥ 0.277 (0.243-0.312) ¥ 0.032 (0.000-0.069) 70.00 (5.23) 61.86 (77.33) 
Depression 0.065 (0.032-0.098) ¥ 0.062 (0.035-0.088) ¥ 0.000 (0.000-0.031) 24.00 (13.79) 24.62 (17.98) 
Bowel cancer 0.120 (0.000-0.284) 0.067 (0.000-0.154) 0.000 (0.000-0.107) 50.0 (49.75) 27.98 (60.55) 
Prostate cancer 0.232 (0.059-0.404) ¥ 0.140 (0.027-0.253) ¥ 0.030 (0.000-0.169) 60.53 (30.42) 44.61 (41.12) 
Breast cancer 0.177 (0.095-0.260) ¥ 0.112 (0.045-0.178) ¥ 0.066 (0.000-0.145) 62.07 (19.05) 61.20 (23.59) 
h2C+R: Common+rare variants; h2C: Common variants, h2R: Rare variants; L: Liability scale; h2SEM: SEM heritability estimates; CI95%: 
Confidence intervals at 95%; SE: Standard errors, ¥; p-value < 0.05 to test the heritability is significantly different from zero. 
 
 
 
 
 
 
 
 
Supplementary Table 15. Heritability estimates from medical records data 
when modelling all SNPs in a single variance component (C+R), or splitting 
common SNPs and rare SNP to estimate two variance components 
simultaneously. 
Disease h2C+R (CI95%)L h2C (CI95%)L h2R (CI95%)L 
Heart Disease 0.138 (0.101-0.175) ¥ 0.110 (0.080-0.140) ¥ 0.012 (0.000-0.046) 
Stroke 0.091 (0.000-0.213)  0.105 (0.000-0.234) 0.000 (0.000-0.165) 
Bronchitis 0.294 (0.130-0.458) ¥ 0.259 (0.118-0.399) ¥ 0.008 (0.000-0.170) 
Hypertension 0.294 (0.274-0.314) ¥ 0.231 (0.214-0.247) ¥  0.034 (0.017-0.050)¥ 
Diabetes 0.329 (0.266-0.393) ¥ 0.265 (0.216-0.314) ¥ 0.000 (0.000-0.055) 
Depression 0.086 (0.055-0.116) ¥ 0.061 (0.036-0.086) ¥ 0.021 (0.000-0.050) 
Bowel cancer 0.034 (0.000-0.184)  0.000 (0.000-0.076) 0.055 (0.000-0.161) 
Prostate cancer 0.329 (0.153-0.505) ¥ 0.199 (0.082-0.316) ¥ 0.049 (0.000-0.188) 
Breast cancer 0.192 (0.107-0.277) ¥ 0.110 (0.044-0.176) ¥ 0.083 (0.000-0.162)¥ 
h2C+R: Common+rare variants; h2C: Common variants, h2R: Rare variants; L: Liability 
scale; ¥; p-value < 0.05 to test the heritability is significantly different from zero. 
 
Supplementary Table 16. Number of significant GWAS hits using self-reported and clinical definitions of disease. 
    Cases Controls Total 
Number 
GWAS hits 
tested 
Number 
significant at  
α = 0.05 
Number 
significant at     
α = 0.00018 
Overlap 
at α = 
0.05 
Overlap at    
α = 0.00018 
Breast cancer Self-reported 2425 57592 60017 48 27 11 22 10 Cancer registry 2339 57678 60017 48 22 10 
Prostate 
cancer 
Self-reported 833 53410 54243 42 21 13 
21 10 Cancer registry 835 53408 54243 42 23 12 
Colorectal 
cancer 
Self-reported 675 113585 114260 23 8 1 
7 1 Clinical/Registry 687 113573 114260 23 8 1 
Type 2 
diabetes 
Self-reported 4670 71722 76392 93 53 28 
49 19 Clinical records 3477 72915 76392 93 49 21 
Hypertension Self-reported 31183 83081 114264 13 10 7 10 6 Clinical records 26201 88063 114264 13 10 6 
Stroke Self-reported 1528 74864 76392 9 1 0 0 0 Clinical records 1107 75285 76392 9 0 0 
Coronary 
heart disease 
Self-reported 7516 68876 76392 46 20 5 
15 4 Clinical records 8435 67957 76392 46 20 5 
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